DOACs/vitamin K antagonists induced hemorrhagic adverse effects; How to bridge therapy before procedures

---

Review Article

Author Details : Ajith Cherian, Naveen Kumar Paramasivan, Divya KP*

Volume : 9, Issue : 2, Year : 2023

Article Page : 66-69

https://doi.org/10.18231/j.ijn.2023.013

Suggest article by email

Get Permission

---

Abstract

Direct oral anticoagulants (DOACs) are emerging as attractive alternatives to vitamin K antagonist which have long been the standard of care in anticoagulation. DOACs are indicated for both prevention and treatment. DOACs have emerged as more effective, safe, and convenient treatment options in thromboembolic settings. With the availability of a gamut of DOACs, clinicians are faced with challenging decisions relating to its hemorrhagic adverse effects. This review will provide an overview on how to manage the hemorrhagic adverse effects of DOACs/vitamin K antagonists and act as a practical guide for clinicians to optimize DOAC use in such challenging scenarios. Topics addressed include transitioning between anticoagulant regimens known as the bridge therapy.
 

Keywords: Anticoagulation, Oral direct thrombin inhibitor, Oral factor Xa inhibitors, Pharmacotherapy

How to cite : Cherian A, Paramasivan N K, Divya Kp, DOACs/vitamin K antagonists induced hemorrhagic adverse effects; How to bridge therapy before procedures. IP Indian J Neurosci 2023;9(2):66-69

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.